Phase 2 study of PB1046 for the treatment of pulmonary arterial hypertension (PAH)

Trial Profile

Phase 2 study of PB1046 for the treatment of pulmonary arterial hypertension (PAH)

Planning
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs PB 1046 (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Nov 2017 Planned initiation date changed from 1 Jan 2017 to 1 Jan 2018, as reported in a PhaseBio Pharmaceuticals media release.
    • 29 Nov 2017 According to a PhaseBio Pharmaceuticals media release, this trial is expected to initiate in 2018.
    • 20 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top